LinkedIn
WebsiteIntroduction
Applied Therapeutics Inc. (NASDAQ: APLT) is a clinical-stage biopharmaceutical company headquartered in New York, New York. As of October 1, 2025, its shares closed at $0.8064, reflecting a 33.31% increase on 7,628,384 shares traded. The company focuses on developing treatments for rare metabolic and genetic diseases by targeting molecules and pathways validated in disease biology.
Corporate Structure
Founded with an experienced leadership team, Applied Therapeutics employs between 11 and 50 people, according to its LinkedIn profile. The company leverages expertise in crystallography and biomarker guidance under FDA policies. Institutional backing includes an 18,683,990-share position (13.2% of outstanding stock) held by T. Rowe Price Investment Management, Inc., as reported in an amended Schedule 13G/A filed on August 14, 2025.
Biopharmaceuticals by little plant
Recent Developments and News
On August 29, 2025, Applied Therapeutics filed an 8-K (items 1.01, 8.01, 9.01) disclosing material corporate events. The same day, it filed a Form 424B5 prospectus supplement detailing an “at-the-market” equity program with Cantor Fitzgerald & Co., authorizing up to $75 million of common stock sales with a commission of 3.0% on the gross proceeds from each sale. In September 2025, the company highlighted its engagement in Charcot-Marie-Tooth (CMT) Awareness Month.
Applied Therapeutics’ pipeline includes:
- govorestat in Phase 3 (with 12-month interim data reported as positive for SORD deficiency)
- govorestat ready for Phase 2 (PMM2-CDG) with expanded access open
- AT-003 Phase 1 ready for diabetic retinopathy
Financial and Strategic Aspects
According to Yahoo Finance as of September 30, 2025, key metrics include:
- Market capitalization: $179.7 million
- 52-week range: $0.2950–10.6240
- Trailing twelve-month revenue: $121,000
- Net loss (TTM): $67.74 million
- Cash on hand (MRQ): $30.42 million
- Total debt/equity (MRQ): 14.92%
- Beta (5Y): 2.06
The controlled equity offering allows the company to raise capital for ongoing clinical trials and expand its pipeline while managing shareholder dilution. Management emphasizes adherence to regulatory compliance in its capital-raising activities.
Market Position and Industry Context
Applied Therapeutics operates in the biotechnology research sector with a focus on rare diseases driven by unmet medical needs. Its approach—utilizing advanced crystallography to design selective aldose reductase inhibitors—distinguishes it from competitors targeting broader metabolic or inflammatory pathways. The company's trading price and beta indicate typical volatility in clinical-stage biotech stocks, while institutional investment and reported positive Phase 3 data support its market position.
tl;dr
On October 1, 2025, APLT shares rose 33.31% to $0.8064 amid significant trading volume. In August 2025, the company established a $75 million ATM equity facility with Cantor Fitzgerald. Its clinical pipeline has shown advancement with reported positive interim Phase 3 data for govorestat in SORD deficiency and readiness for Phase 2 in PMM2-CDG. With $30.42 million in cash and backing from institutional investors, future developments may include full Phase 3 results and ongoing equity sales through the at-the-market program.
